Uniseed has entered a co-investment pact with BioCurate, a drug discovery fund for early-stage University of Melbourne and Monash University research.
BioCurate, a state government-backed medical research engine formed by University of Melbourne and Monash University, joined forces with multi-university venturing fund Uniseed in a commercialisation and development partnership yesterday.
The agreement will form the basis for co-investment opportunities between BioCurate and Uniseed targeting drug research and therapeutics.
Founded in 2016 with A$25m ($17.1m) each from University of Melbourne and Monash University, BioCurate is intended to facilitate the development of new medicines by investing in early-stage research from both institutions.
BioCurate, which unveiled its first six projects in July 2018, is also supported by a A$10m grant from the Victorian state government. Its portfolio includes three preclinical cancer targets, anti-bacterial, viral and parasitic drug candidates, and projects relating to epilepsy, muscle disease and fibrosis.
Uniseed’s chief executive, Peter Devine, said: “We are excited to enter this collaboration with BioCurate, as it will ensure early-stage drug and therapeutic…
